Business Combinations and Contingent Consideration - Acquisition-Date Fair Value of Consideration Transferred (Detail) (Captisol-enabled, propylene glycol-free melphalan rights [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Captisol-enabled, propylene glycol-free melphalan rights [Member]
Business Acquisition [Line Items]
Cash consideration	$ 3,000
Ligand Contingent Consideration	4,700
Total purchase consideration	$ 7,700